A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing ...
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid ...
InvestorsHub on MSN
Adaptive Biotechnologies enters two TCR licensing agreements with Pfizer
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has entered into two separate agreements with Pfizer Inc. (NYSE:PFE) that will see the companies collaborate on T-cell receptor (TCR) research to ...
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...
A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in ...
An evolutionary perspective on immune priming across plants and invertebrates highlights the roles of microbiomes and epigenetic regulation in shaping innate immune memory with promising applications ...
Mucosal surfaces serve as critical battlegrounds where the immune system must balance tolerance to commensal organisms with rapid defense against pathogens.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback